Juvenile idiopathic arthritis is the most common autoimmune disease in childhood—the incidence among children under 16 is approximately 1 in 1,000. Early diagnosis and appropriate treatment remain a challenge. As part of a multidisciplinary approach, collaboration between primary care physicians and specialists in rheumatology—as well as other relevant disciplines when necessary—is crucial for achieving the best possible long-term outcomes. A wide range of disease-modifying medications (csDMARDs, bDMARDs, tsDMARDs) is now available as first-line therapy.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
- InFo RHEUMATOLOGIE
Related Topics
- Abatacept
- Arava
- Arthritis
- Autoimmune disease
- bDMARDs
- Biologics
- Canakinumab
- Childhood
- csDMARDs
- disease-modifying drugs
- Early detection
- Essential Medications
- Hydroxychloroquine
- Ilaris
- Infliximab
- interdisciplinary setting
- JAK-i
- jiA
- Juvenile idiopathic arthritis
- Leflunomide
- MTX
- Orencia
- Remicade
- Rheumatology
- Sulfasalazine
- targeted treatment
- tsDMARDs
- Uveitis
You May Also Like
- Myasthenia gravis: immunomodulatory therapies for long-term treatment
Expanded Possibilities Thanks to Innovative Classes of Active Ingredients
- Plastic surgery and reconstructive microsurgery for DFS
Functional limb preservation between infection control, vascular medicine and resurfacing
- Interstitial Lung Diseases
Update on Idiopathic Pulmonary Fibrosis
- Ischemic stroke: Are smaller or larger brain arteries affected?
Recent study findings on intravenous lysis therapy with fibrinolytic agents
- Interview
“On par with the gold standards for trauma”
- Psychology: Emotional Freedom Techniques (EFT)
Emotional Healing Through Tapping
- Systemic Lupus (SLE): What Does the Diagnosis and Treatment Toolbox Have to Offer?
Treat-to-Target – Consensus Recommendations for GC Tapering and the Use of DMARDs
- Interstitial Lung Diseases